Index by author

June 2006; Volume 47,Issue 6

  1. Abanades, Sergi

    1. Characterization of the SPECT 5-HT2A Receptor Ligand 123I-R91150 in Healthy Volunteers: Part 2—Ketanserin Displacement
      Ana M. Catafau, Monica Danus, Santiago Bullich, Gianluca Nucci, Jordi Llop, Sergi Abanades, Vincent J. Cunningham, Jos L.H. Eersels, Javier Pavia and Magi Farre
      Journal of Nuclear Medicine June 1, 2006, 47 (6) 929-937;

  2. Akabani, Gamal

    1. Novel Human IgG2b/Murine Chimeric Antitenascin Monoclonal Antibody Construct Radiolabeled with 131I and Administered into the Surgically Created Resection Cavity of Patients with Malignant Glioma: Phase I Trial Results
      David A. Reardon, Jennifer A. Quinn, Gamal Akabani, R. Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Roger E. McLendon, Charles N. Pegram, James M. Provenzale, Jeannette M. Dowell, Jeremy N. Rich, James J. Vredenburgh, Annick Desjardins, John H. Sampson, Sridharan Gururangan, Terence Z. Wong, Michael A. Badruddoja, Xiao-Guang Zhao, Darell D. Bigner and Michael R. Zalutsky
      Journal of Nuclear Medicine June 1, 2006, 47 (6) 912-918;

  3. Askoxylakis, Vasileios

    1. Characterization and Development of a Peptide (p160) with Affinity for Neuroblastoma Cells
      Vasileios Askoxylakis, Walter Mier, Sabine Zitzmann, Volker Ehemann, Jianbing Zhang, Susanne Krämer, Carmen Beck, Manfred Schwab, Michael Eisenhut and Uwe Haberkorn
      Journal of Nuclear Medicine June 1, 2006, 47 (6) 981-988;

  4. Bacharach, Steve

    1. Consensus Recommendations for the Use of 18F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials
      Lalitha K. Shankar, John M. Hoffman, Steve Bacharach, Michael M. Graham, Joel Karp, Adriaan A. Lammertsma, Steven Larson, David A. Mankoff, Barry A. Siegel, Annick Van den Abbeele, Jeffrey Yap and Daniel Sullivan
      Journal of Nuclear Medicine June 1, 2006, 47 (6) 1059-1066;

  5. Badruddoja, Michael A.

    1. Novel Human IgG2b/Murine Chimeric Antitenascin Monoclonal Antibody Construct Radiolabeled with 131I and Administered into the Surgically Created Resection Cavity of Patients with Malignant Glioma: Phase I Trial Results
      David A. Reardon, Jennifer A. Quinn, Gamal Akabani, R. Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Roger E. McLendon, Charles N. Pegram, James M. Provenzale, Jeannette M. Dowell, Jeremy N. Rich, James J. Vredenburgh, Annick Desjardins, John H. Sampson, Sridharan Gururangan, Terence Z. Wong, Michael A. Badruddoja, Xiao-Guang Zhao, Darell D. Bigner and Michael R. Zalutsky
      Journal of Nuclear Medicine June 1, 2006, 47 (6) 912-918;

  6. Barbanoj, Manel

    1. Characterization of the SPECT 5-HT2A Receptor Ligand 123I-R91150 in Healthy Volunteers: Part 1—Pseudoequilibrium Interval and Quantification Methods
      Ana M. Catafau, Monica Danus, Santiago Bullich, Jordi Llop, Javier Perich, Vincent J. Cunningham, Pedro Plaza, Maria M. Penengo, Jos L.H. Eersels, Lisa Squassante, Domenec Ros and Manel Barbanoj
      Journal of Nuclear Medicine June 1, 2006, 47 (6) 919-928;

  7. Beck, Carmen

    1. Characterization and Development of a Peptide (p160) with Affinity for Neuroblastoma Cells
      Vasileios Askoxylakis, Walter Mier, Sabine Zitzmann, Volker Ehemann, Jianbing Zhang, Susanne Krämer, Carmen Beck, Manfred Schwab, Michael Eisenhut and Uwe Haberkorn
      Journal of Nuclear Medicine June 1, 2006, 47 (6) 981-988;

  8. Beer, Ambros J.

    1. Value of 11C-Choline PET and Contrast-Enhanced CT for Staging of Bladder Cancer: Correlation with Histopathologic Findings
      Maria Picchio, Uwe Treiber, Ambros J. Beer, Stefan Metz, Patrick Bössner, Heiner van Randenborgh, Roger Paul, Gregor Weirich, Michael Souvatzoglou, Rudolf Hartung, Markus Schwaiger and Morand Piert
      Journal of Nuclear Medicine June 1, 2006, 47 (6) 938-944;

  9. Belhocine, Tarik Z.

    1. Role of Nuclear Medicine in the Management of Cutaneous Malignant Melanoma
      Tarik Z. Belhocine, Andrew M. Scott, Einat Even-Sapir, Jean-Luc Urbain and Richard Essner
      Journal of Nuclear Medicine June 1, 2006, 47 (6) 957-967;

  10. Bigner, Darell D.

    1. Novel Human IgG2b/Murine Chimeric Antitenascin Monoclonal Antibody Construct Radiolabeled with 131I and Administered into the Surgically Created Resection Cavity of Patients with Malignant Glioma: Phase I Trial Results
      David A. Reardon, Jennifer A. Quinn, Gamal Akabani, R. Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Roger E. McLendon, Charles N. Pegram, James M. Provenzale, Jeannette M. Dowell, Jeremy N. Rich, James J. Vredenburgh, Annick Desjardins, John H. Sampson, Sridharan Gururangan, Terence Z. Wong, Michael A. Badruddoja, Xiao-Guang Zhao, Darell D. Bigner and Michael R. Zalutsky
      Journal of Nuclear Medicine June 1, 2006, 47 (6) 912-918;
« Previous (Pages : 1 2 3 4 5 6 ... 18) Next »
Back to top

In this issue